Fernanda Musa @fmusaMD X Profile

Fernanda Musa

@fmusaMD

Followers

501

Following

624

Media

58

Statuses

443

Gyn Oncologist at Swedish Cancer Institute, Seattle; Clinical Trialist; SGO member; Mom x 3

Joined March 2014

Don't wanna be here? Send us removal request.

Fernanda Musa

@fmusaMD

2 years

https://t.co/jrGwLi7oiB

0

2

3

SGO

@SGO_org

2 years

SGO member @fmusaMD featured in the @seattletimes

seattletimes.com

Washington doctors and other health care providers are confronting moral quandaries as they draw up guidelines to ration lifesaving chemotherapy drugs.

1

2

4

Shannon Westin, MD, MPH, FASCO

@ShannonWestin

2 years

🙌 Really exciting data presented by Dr. Moore on DB-1303- this #HER2 #AntibodyDrugConjugate demonstrated 44% response rate in heavily pre-treated patients! #ASCO23 #gyncsm

1

7

22

Annie Ellis

@Stigetta

2 years

LBA Kathleen Moore: MIRASOL Practice changing! Confirms SORAYA. Mirvetuximab new SOC in folate receptor alpha platinum-resistant ovarian cancer! #ASCO23 #gyncsm

0

9

25

Shannon Westin, MD, MPH, FASCO

@ShannonWestin

2 years

👀this is the FIRST TRIAL to show overall survival benefit in platinum resistant #OvarianCancer. 🙌Standard of care is clear! 🧐Get the FOLR1 testing and identify the patients that will benefit from mirvetuximab #ASCO23 #gyncsm

Eleonora Teplinsky, MD, FASCO

@drteplinsky

2 years

🚨Amazing to see ⬆️ in overall survival for mirvetixumab in FOLR1 positive platinum resistant #ovariancancer. Absolutely new standard of care!! 👏 #gyncsm #ASCO23

0

35

94

Ali Saiz, MD MS

@AllisonSaizMD

2 years

Celebrating the end of a successful @SGO_org / @GYNCancer Strategic Meeting Day with @fmusaMD @KDRichardson924 @amandanfader @msshahin @LPrescottMD #SGOMtg

1

15

Ali Saiz, MD MS

@AllisonSaizMD

2 years

Up and at ‘em with an early morning Chicago running tour - @SGO_org style with @LPrescottMD @BarbaraAGoff @StephanieVBlank @fmusaMD Kickstarting our discussion of @GYNCancer Strategic Planning #SGOMtg

2

1

16

Ane Gerda Z Eriksson MD PhD

@agz_eriksson

2 years

DUO-E improves PFS in women w advanced stage #EndometrialCancer @OncoAlert @ESGO_society @IGCSociety https://t.co/4457CAyF6D

astrazeneca.com

Shannon Westin, MD, MPH, FASCO

@ShannonWestin

2 years

🙌So excited to share our study DUO-E/GOG3041/ENGOT-EN10 demonstrated the addition of durvalumab + olaparib or durvalumab alone to chemotherapy/maintenance improves progression free survival in patients w/ advanced/recurrent #EndometrialCancer 🥰It's a very good day for #gyncsm

0

7

15

Amanda Nickles Fader, MD

@amandanfader

3 years

Please join us as we discuss strategies to optimize care for our pts and support providers during this challenging time of chemo shortages. Grateful for wonderful, expert webinar colleagues, including @NavyaNairMD, @drleslie214 @ROCearbhaill, @fmusaMD,& Drs Einstein and Shuey.

0

3

12

Annie Ellis

@Stigetta

3 years

Celebrating 25 years of AACR’s Scientist↔️Survivor Program! Bringing together patients, patient advocates and researchers. #AACRSSP #AACR23 Encouraging partnerships and collaborations to infuse science with patient perspectives and empower advocates to engage in research.

0

6

15

Duke Ob/Gyn

@dukeobgyn

3 years

Congratulations to @AngelesSecord on her award for 2022 Best Clinical Practice Abstract (presented at the 2023 @SGO_org Annual Meeting) and for her new role as president of @SGO_org! #WomensHistoryMonth #NationalDoctorsDay

2

4

25

Annie Ellis

@Stigetta

3 years

Dr Sarah Lee: Gynecologic cancer trends by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis #SGOmtg #gyncsm #PatientsPurposeProgress More work needed to disaggregate!

0

1

4

Daniela Matei

@matei_dem

3 years

Honored to report the final results of #GOG 258 @SGOmtg. Addition of radiation to chemotherapy does not improve overall survival for stage III #endometrialcancer. @LurieCancer #NorthwesternMed.

4

11

74

Dee Sparacio

@womenofteal

3 years

Way to go @Stigetta patient advocate speaking at a Scientific Plenary session Long-term survivors speak: patient perspectives on progress #SGOMtg #PatientsPurposeProgress #gyncsm

0

5

17

Providence Swedish Cancer Institute Research

@ProvSwedCancRes

3 years

Dr. Musa @ProvSwedish @ProvSwedCancRes contributes to SGO summit report on the future of gyn-onc

pubmed.ncbi.nlm.nih.gov

The original vision of the field of gynecologic oncology was to establish a multidisciplinary approach to the management of patients with gynecologic cancers. Fifty years later, scientific advances...

0

3

4

Providence Swedish Cancer Institute Research

@ProvSwedCancRes

3 years

Congrats Dr. Musa and the @ProvSwedCancRes @ProvSwedish on your contributions to this practice changing study!

NEJM

@NEJM

3 years

Late breaking at #SGOMtg: In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than chemotherapy alone. https://t.co/dTyV1zTO0I

0

3

7

David Cohn, MD, MBA

@David_Cohn_MD

3 years

It's a great day for #GynOnc research, with new findings showing significant progression-free survival improvement for some #immunotherapy/chemo combos. Here's a look at one study focusing on advanced endometrial cancer, conducted in part by the @OSUCCC_James' @FBackesMD. (1/2)

2

9

70

Bhavana Pothuri

@BPothuri

3 years

LBA happening now! ⁦@rne_md⁩ and Dr. Mirza about to present GY-O18 and RUBY #sgo2023 and change the frontline treatment of endometrial cancer @sgo ⁦@GOG⁩ ⁦@gyncsm⁩ @acog @asco

0

2

35

Shannon Westin, MD, MPH, FASCO

@ShannonWestin

3 years

🧐 How were they different?? @ArendRebecca distills the details of RUBY and GY018. Bottom line - practice changing for #EndometrialCancer + great representation of typically underrepresented minority volunteers == A HOME RUN! #SGOMtg #gyncsm #ImmunoOnc

0

15

55

Annie Ellis

@Stigetta

3 years

Endometrial cancer patient @researchmatters thanks @SGO_org for all the hard work. Standing ovation!! #SGOmtg #PatientsPurposeProgress #gyncsm

2

9

50